ASX 300

Former Pilbara chief says history set to repeat; Neil Biddle now into helium at Greenvale and Spartan gets big price target as gold jumps.

Rising bond yields and higher interest rate expectations has not been a good backdrop for stocks, but these three stocks are positive.

In this episode, Perpetual’s Anthony Aboud and WaveStone's Catherine Allfrey analyse three stalwart ASX stocks.

The daily Match Out for Thursday 19 October 2023 with James Gerrish of Market Matters.

Market volatility is uncomfortable but during such periods, listed property assets may provide attractive return opportunities.

Listed investment company-focused fund manager Daryl Wilson explains why and names a few he's watching most closely

Get up to date on overnight market activity and the big events for the day.

The daily Match Out for Wednesday 18 October 2023 with James Gerrish of Market Matters

In a matter of weeks, uranium prices have pushed to 16-year highs. But does the rally have more legs to run? Or is the best behind us?

NovaPort’s Tim Binsted outlines the bull case for Mondelphous, which includes dividends, quality management, and a strong balance sheet.

Don’t always have the free cash to buy more shares in your favourite company? A dividend reinvestment plan could be the answer.

The daily Match Out for Tuesday 17 October 2023 with James Gerrish of Market Matters

Acorn Capital's Rick Squire schools investors on how best to invest in commodity stocks today.

Learn about the options available for generating passive income with ETFs, plus a popular strategy for investors in draw-down.

Get up to date on overnight market activity and the big events for the day.

The daily Match Out for Monday 16 October 2023 with James Gerrish of Market Matters.

Wealth manager Hugh Robertson discusses the biggest concerns alongside some preferred sectors and stocks to help ride out uncertainty.

Albemarle has walked away from its $6.6 billion bid for Liontown. So what's next for the ASX's next hard rock lithium producer?

Recession signals have been flashing red for some time, but the strength of labour markets and resilient consumer spending is suggesting that Australia might be in for...

Miracle weight loss drugs are providing opportunity in the Healthcare sector, and its not Novo-Nordisk

The market is expecting a revised takeover offer from the Brookfield consortium. So what does the upside look like?

Allan Gray's Simon Mawhinney explains the virtues of being a patient investor, particularly when the immediate evidence is less than ideal.

We recap some of the bottom-drawer stocks named by several of Australia's best fund managers on Livewire's Rules of Investing podcast

Weekly Update | 13th October, 2023